{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:19:48Z","timestamp":1787167188587,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T00:00:00Z","timestamp":1597968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1038\/s41440-020-00535-8","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T21:02:28Z","timestamp":1597957348000},"page":"1257-1266","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Renin\u2013angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study"],"prefix":"10.1038","volume":"43","author":[{"given":"Yasushi","family":"Matsuzawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisao","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaaki","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Kirigaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Fukui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tsukahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Iwabuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Saka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouichi","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,21]]},"reference":[{"key":"535_CR1","doi-asserted-by":"publisher","unstructured":"Itoh H. A new normal for hypertension medicine with coronavirus disease-2019 (COVID-19): proposal from the president of the Japanese Society of Hypertension. Hypertens Res. 2020. https:\/\/doi.org\/10.1038\/s41440-020-0497-y) [Epub ahead of print].","DOI":"10.1038\/s41440-020-0497-y"},{"key":"535_CR2","doi-asserted-by":"publisher","unstructured":"Shibata S, Arima H, Asayama K, Hoshide S, Ichihara A, Ishimitsu T, et al. Hypertension and related diseases in the era of COVID-19; a report from the Japanese Society of Hypertension Task Force on COVID-19. Hypertens Res. 2020. https:\/\/doi.org\/10.1038\/s41440-020-0515-0) [Epub ahead of print].","DOI":"10.1038\/s41440-020-0515-0"},{"key":"535_CR3","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jama.290.3.374","volume":"290","author":"TW Lew","year":"2003","unstructured":"Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. JAMA. 2003;290:374\u201380.","journal-title":"JAMA."},{"key":"535_CR4","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"JS Peiris","year":"2003","unstructured":"Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361:1767\u201372.","journal-title":"Lancet."},{"key":"535_CR5","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1016\/S0140-6736(03)13413-7","volume":"361","author":"JM Nicholls","year":"2003","unstructured":"Nicholls JM, Poon LL, Lee KC, Ng WF, Lai ST, Leung CY, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773\u20138.","journal-title":"Lancet."},{"key":"535_CR6","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","volume":"111","author":"CM Ferrario","year":"2005","unstructured":"Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111:2605\u201310.","journal-title":"Circulation."},{"key":"535_CR7","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/ajh\/hpu086","volume":"28","author":"M Furuhashi","year":"2015","unstructured":"Furuhashi M, Moniwa N, Mita T, Fuseya T, Ishimura S, Ohno K, et al. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker. Am J Hypertens. 2015;28:15\u201321.","journal-title":"Am J Hypertens"},{"key":"535_CR8","doi-asserted-by":"publisher","unstructured":"Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;e201855. https:\/\/doi.org\/10.1001\/jamacardio.2020.1855 [Epub ahead of print].","DOI":"10.1001\/jamacardio.2020.1855"},{"key":"535_CR9","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2006923","volume":"382","author":"G Mancia","year":"2020","unstructured":"Mancia G, Rea F, Ludergnani M, Apolone G, Corrao G. Renin-Angiotensin-Aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020;382:2431\u201340.","journal-title":"N Engl J Med"},{"key":"535_CR10","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/s41440-020-0455-8","volume":"43","author":"H Kai","year":"2020","unstructured":"Kai H, Kai M. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19. Hypertens Res. 2020;43:648\u201354.","journal-title":"Hypertens Res."},{"key":"535_CR11","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nrmicro.2016.81","volume":"14","author":"E de Wit","year":"2016","unstructured":"de Wit E, van Doremalen N, Falzarano D, Munster VJ. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523\u201334.","journal-title":"Nat Rev Microbiol"},{"key":"535_CR12","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1038\/nm1267","volume":"11","author":"K Kuba","year":"2005","unstructured":"Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875\u20139.","journal-title":"Nat Med."},{"key":"535_CR13","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s11427-020-1643-8","volume":"63","author":"Y Liu","year":"2020","unstructured":"Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63:364\u201374.","journal-title":"Sci China Life Sci"},{"key":"535_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/j.immuni.2020.04.003","volume":"52","author":"T Hirano","year":"2020","unstructured":"Hirano T, Murakami M. COVID-19: a new virus, but a familiar receptor and cytokine release syndrome. Immunity. 2020;52:731\u20133.","journal-title":"Immunity."},{"key":"535_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature."},{"key":"535_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms4594","volume":"5","author":"Z Zou","year":"2014","unstructured":"Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594.","journal-title":"Nat Commun."},{"key":"535_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/srep19840","volume":"6","author":"H Gu","year":"2016","unstructured":"Gu H, Xie Z, Li T, Zhang S, Lai C, Zhu P, et al. Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus. Sci Rep. 2016;6:19840.","journal-title":"Sci Rep."},{"key":"535_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2020.1624","volume":"5","author":"J Li","year":"2020","unstructured":"Li J, Wang X, Chen J, Zhang H, Deng A. Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China. JAMA Cardiol. 2020;5:1\u20136. https:\/\/doi.org\/10.1001\/jamacardio.2020.1624. [Epub ahead of print].","journal-title":"JAMA Cardiol"},{"key":"535_CR19","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1080\/22221751.2020.1746200","volume":"9","author":"J Meng","year":"2020","unstructured":"Meng J, Xiao G, Zhang J, He X, Ou M, Bi J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9:757\u201360.","journal-title":"Emerg Microbes Infect"},{"key":"535_CR20","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1161\/CIRCRESAHA.120.317134","volume":"126","author":"P Zhang","year":"2020","unstructured":"Zhang P, Zhu L, Cai J, Lei F, Qin JJ, Xie J, et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126:1671\u201381.","journal-title":"Circ Res."},{"key":"535_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13054-020-02882-x","volume":"24","author":"K Kotfis","year":"2020","unstructured":"Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24:176.","journal-title":"Crit Care."},{"key":"535_CR22","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s00401-010-0674-1","volume":"119","author":"J Cerejeira","year":"2010","unstructured":"Cerejeira J, Firmino H, Vaz-Serra A, Mukaetova-Ladinska EB. The neuroinflammatory hypothesis of delirium. Acta Neuropathol. 2010;119:737\u201354.","journal-title":"Acta Neuropathol."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00535-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00535-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T19:26:08Z","timestamp":1629487568000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00535-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,21]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["535"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-00535-8","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,21]]},"assertion":[{"value":"2 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"K Tamura has received lecture fees from Daiichi-Sankyo, Mochida, Kyowa Kirin, Boehringer Ingelheim Japan, Dainippon-Sumitomo, Takeda, and AstraZeneca and has received research grants from AstraZeneca, Ono Pharmaceutical, Boehringer Ingelheim Japan, Teijin Pharma, Mochida, Daiichi-Sankyo, Takeda, Kyowa Kirin, Dainippon-Sumitomo, Tsumura, and Bayer Japan outside the submitted work. The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}